

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

Single Technology Appraisal

Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No additional equalities issues were identified from consultees. No changes have been made to the draft scope regarding equalities issues.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No equality issues have been raised in submissions, expert statements or academic reports.
--

- | |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

No equality issues have been identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

The Committee's considerations of equality have been described in section 4.19 of the second appraisal consultation document issued August 2010.

Approved by Associate Director (name): ...Helen Chung.....

Date: 7 December 2010

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No equality issues have been raised during consultation.

2. If the recommendations have changed after consultation, are there

any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups?
If so, what are the barriers to access for the specific group?

Not applicable.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The Committee's considerations of equality issues have been described in section 4.23 of the final appraisal determination.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 7 December 2010